Market Place
Sourcing Support
BerGenBio Announces Data Indicating Broadened Potential for Bemcentinib
07 Feb 2024 //
PR NEWSWIRE
Data on BerGenBio`s selective AXL inhibitor bemcentinib to be presented
16 Oct 2023 //
PR NEWSWIRE
BerGenBio announces data presentations showing activity of bemcentinib in NSCLC
22 Aug 2023 //
PR NEWSWIRE
BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib
09 Mar 2023 //
PR NEWSWIRE
BerGenBio randomises first patient in Covid-19 treatment study
28 Sep 2022 //
CLINICALTRIALSARENA
BerGenBio, Oslo University`s Bemcentinib will be Studied in EU-SolidAct trial
27 Jan 2022 //
PRNEWSWIRE
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11 (NSCLC)
09 Nov 2021 //
PRNEWSWIRE
BerGenBio Receives Fast Track Designation For Bemcentinib / Anti-PD-(L)1
08 Jun 2021 //
PRNEWSWIRE
BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib
14 Jun 2020 //
PRNEWSWIRE
First patient dosed in bemcentinib COVID-19 trial
02 Jun 2020 //
PHARMA TIMES
UK hospitals to trial five new drugs in search for coronavirus treatment
02 Jun 2020 //
THEGUARDIAN
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial
01 Jun 2020 //
PRNEWSWIRE
BerGenBio`s Bemcentinib Selected to be Fast-tracked as Treatment for COVID-19
28 Apr 2020 //
PR NEWSWIRE
BerGenBio`s Bemcentinib Selected to Be Fast-tracked As for COVID-19
28 Apr 2020 //
PR NEWSWIRE
BerGenBio Meets Endpoint For First Stage Of Phase II Trial With Bemcentinib
15 Jan 2020 //
PR NEWSWIRE
BerGenBio Presents Preliminary Clinical Data From Ph II Combo Trial Bemcentinib
09 Dec 2019 //
PR NEWSWIRE
Piramal Pharma Solutions partners with BerGenBio to develop blood cancer drug
03 Dec 2019 //
MONEY CONTROL
Lynparza shows benefits in prostate cancer
03 Dec 2019 //
PHARMA TIMES
Bemcentinib, Keytruda combo hits endpoints in mid-stage NSCLC trial
08 Nov 2019 //
PHARMATIMES
BerGenBio to Present Clinical Data From PhII Combination Trial of Bemcentinib
07 Nov 2019 //
PR NEWSWIRE
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
22 Oct 2019 //
PR NEWSWIRE
Regeneron, ArQule track progress on response rates
17 Jun 2019 //
ENDPTS
BerGenBio posts updated data on trial of elderly AML patients
17 Jun 2019 //
FIERCE BIOTECH
BerGenBio Presents New Preliminary Clinical and Biomarker Data
04 Jun 2019 //
PR NEWSWIRE
Piramal Pharma collaborates with BerGenBio
19 Mar 2019 //
BIOSPECTRUMINDIA
BerGenBio to Present on Phase II Trial of Bemcentinib+KEYTRUDA in Adv NSCLC
01 Nov 2018 //
PR NEWSWIRE
BerGenBio Enters2nd Stage of Phase II Trial with bemcentinib+KEYTRUDA in NSCLC
05 Oct 2018 //
PR NEWSWIRE
BerGenBio to Present Interim Clinical Data on Bemcentinib in AML and MDS at EHA
18 May 2018 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.